Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In critical care, hemodynamic instability often requires volume expansion to restore tissue perfusion, increasing fluid balance and TBW, factors associated with higher mortality. Excess fluid leads to organ dysfunction due to venous congestion, making fluid removal crucial. When diuretics fail, RRT, typically through continuous renal replacement therapy (CRRT), is recommended. However, prescribing the correct level of UF is challenging; insufficient UF can worsen edema, while excessive UF risks hemodynamic instability. This pilot, single-center, prospective, interventional, randomized, controlled, open-label study includes two parallel groups: a standard group with UF prescribed by the physician based on clinical and hemodynamic status and an experimental group with UF guided by the extracellular to total body water (ECW/TBWat) ratio measured by BIA. The aim is to determine if ECW/TBW-guided UF improves fluid and TBW reduction over a 72-hour RRT period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Free UF Prescription | Active Comparator | Free UF Prescription : The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition. |
|
| UF Prescription Guided by the ECW/TBWat Ratio | Experimental | Experimental Group - UF Prescription Guided by the ECW/TBWat Ratio :
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| continuous renal replacement therapy (CRRT) | Procedure | The patient is included in the study once they meet the eligibility criteria and as soon as the responsible physician has prescribed RRT according to the department's protocol. Randomization will be performed, and the patient will be assigned to either the standard or experimental groups. |
| Measure | Description | Time Frame |
|---|---|---|
| comparison of TBW between both groups | To assess the impact of UF prescription guided by the ECW/TBWat ratio on weight loss, a comparison of TBW (∆TBW) between the two groups will be conducted. The ∆TBW is the difference between the initial TBW at H0 and the TBW at H72. | at 72 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Variation of cumulative net UF | The net UF is the difference between the fluids removed by RRT and the replacement fluids infused before and after the RRT filter. The cumulative net UF is the UF measured from H0 to H72. The volume of UF and infused replacement fluid will be calculated using data extracted from the memory card of the RRT machine. | at 72 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Christophe Beyls, MD | Contact | 33 + 03 22 08 78 66 | beyls.christophe@chu-amiens.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU Amiens | Recruiting | Salouël | 80480 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Pilot, Controlled, Open-Label, Randomized Study
Not provided
Not provided
Not provided
Not provided
|
| Free UF Prescription | Other | The UF (ml/h) is prescribed by the responsible physician based on the patient's clinical, congestive, and hemodynamic status. The physician can implement the UF whenever necessary based on the patient's hemodynamic condition. |
|
| Measurement of the net UF rate | Measurement of the net UF rate (ml/kg/h): The net UF rate is calculated as follows: cumulative net UF / (TBW at H0) x effective treatment duration during the 72 hours of the study. The treatment duration will be measured using data extracted from the memory card of the RRT machine. | at 72 hours |
| Measurement of the ECW/TBWATratio and its association with the VeXUS score | Measurement of the ECW/TBWATratio and its association with the VeXUS score at H0 . The VeXUS score is an echocardiographic score (ranging from 0 to 3) used to analyze venous congestion at the cardiac, renal, and hepatic levels. | day 0 |
| Measurement of the ECW/TBWATratio and its association with the VeXUS score | Measurement of the ECW/TBWATratio and its association with the VeXUS score at H72 . The VeXUS score is an echocardiographic score (ranging from 0 to 3) used to analyze venous congestion at the cardiac, renal, and hepatic levels. | at 72 hours |
| Measurement of the ECW/TBWAT ratio | Measurement of the ECW/TBWATratio and its association with conventional right heart function parameters and those evaluated by speckle tracking at H0. The speckle tracking-based parameters used will measure: (a) Longitudinal displacement of the septal and lateral walls and right ventricular shortening; (b) Global longitudinal strain and free wall strain of the right ventricle and (c) Right atrial strain (reservoir, conduit, and contraction phases). The parameters will be measured offline using the QLAB 15.0 software (Philips Healthcare). | day 0 |
| Measurement of the ECW/TBWAT ratio | Measurement of the ECW/TBWATratio and its association with conventional right heart function parameters and those evaluated by speckle tracking at H72. The speckle tracking-based parameters used will measure: (a) Longitudinal displacement of the septal and lateral walls and right ventricular shortening; (b) Global longitudinal strain and free wall strain of the right ventricle and (c) Right atrial strain (reservoir, conduit, and contraction phases). The parameters will be measured offline using the QLAB 15.0 software (Philips Healthcare). | 72 hours |
| number of filters used in both groups | Reporting of complications related to RRT in both groups : number of filters used | at 24 hours |
| number of filters used in both groups | Reporting of complications related to RRT in both groups : number of filters used | at 48 hours |
| number of filters used in both groups | Reporting of complications related to RRT in both groups : number of filters used | at 72 hours |
| duration of use for each filter in both groups | complications related to RRT in both groups : duration of use for each filter in both groups | at 24 hours |
| duration of use for each filter in both groups | complications related to RRT in both groups : duration of use for each filter in both groups | at 48 hours |
| duration of use for each filter in both groups | complications related to RRT in both groups : duration of use for each filter in both groups | at 72 hours |
| Number of hypotensive episodes during dialysis | Number of hypotensive episodes during dialysis: A hypotensive episode is defined as a mean arterial pressure (MAP) < 65 mmHg for 1 minute, measured using hemodynamic monitoring | at 24 hours |
| Number of hypotensive episodes during dialysis | Number of hypotensive episodes during dialysis: A hypotensive episode is defined as a mean arterial pressure (MAP) < 65 mmHg for 1 minute, measured using hemodynamic monitoring | at 48 hours |
| Number of hypotensive episodes during dialysis | Number of hypotensive episodes during dialysis: A hypotensive episode is defined as a mean arterial pressure (MAP) < 65 mmHg for 1 minute, measured using hemodynamic monitoring | at 72 hours |
| Number of arrhythmias in both groups | Number of arrhythmias in both groups | at 24 hours |
| Number of arrhythmias in both groups | Number of arrhythmias in both groups | at 48 hours |
| Number of arrhythmias in both groups | Number of arrhythmias in both groups | at 72 hours |
| Number of arrhythmias with hemodynamic instability | Number of arrhythmias with hemodynamic instability | at 24 hours |
| Number of arrhythmias with hemodynamic instability | Number of arrhythmias with hemodynamic instability | at 48 hours |
| Number of arrhythmias with hemodynamic instability | Number of arrhythmias with hemodynamic instability | at 72 hours |
| Measurement of serum potassium | Measurement of serum potassium | at 24 hours |
| Measurement of serum potassium | Measurement of serum potassium | at 48 hours |
| Measurement of serum potassium | Measurement of serum potassium | at 72 hours |
| Measurement of serum phosphate | Measurement of serum phosphate | at 24 hours |
| Measurement of serum phosphate | Measurement of serum phosphate | at 48 hours |
| Measurement of serum phosphate | Measurement of serum phosphate | at 72 hours |
| Cumulative volume of crystalloid administration | Cumulative volume of crystalloid administration | at 72 hours |
| Cumulative volume of colloid administration | Cumulative volume of colloid administration | at 72 hours |
| Cumulative dose of norepinephrine administration | Cumulative dose of norepinephrine administration | at 72 hours |
| Duration of norepinephrine administration | Duration of norepinephrine administration | at 72 hours |
| Duration of mechanical ventilation | Duration of mechanical ventilation | at day 30 |
| 30-day mortality | 30-day mortality | at day 30 |
| Length of stay in intensive care | Length of stay in intensive care | at day 30 |
| Length of stay at the hospital | Length of stay at the hospital | at day 30 |
| ID | Term |
|---|---|
| D000079664 | Continuous Renal Replacement Therapy |
| ID | Term |
|---|---|
| D017582 | Renal Replacement Therapy |
| D013812 | Therapeutics |
| D005112 | Extracorporeal Circulation |
| D013514 | Surgical Procedures, Operative |
Not provided
Not provided